{
    "nct_id": "NCT03239223",
    "official_title": "A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL)",
    "inclusion_criteria": "* Women, 25 to 50 years old.\n* Cervical HSIL diagnosis made within 2 months of enrollment and confirmed with biopsy with no evidence of invasive cancer in any specimen and must be p16+.\n* Able and willing to abstain from sexual intercourse for 48 hours prior to first dose and 2 days after each dose.\n* Generally experiencing regular menstrual cycles, unless using long-acting reversible contraception that induces amenorrhea (e.g., Mirena IUD, Norplant).\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 25 Years\nMust have maximum age of 50 Years",
    "exclusion_criteria": "* Women who are pregnant, plan to become pregnant in the next 4 months, or lactating females.\n* History of cancer, except basal cell or squamous cell carcinoma of the skin.\n* History of genital herpes with > 3 outbreaks per year, or active non-HPV vaginal infection.\n* Plan to have excision or ablation of the lesion(s) within 3 months of enrollment.\n* History of cervical cancer, colposcopy suspicious for cancer, any prior treatment of CIN, or hysterectomy.",
    "miscellaneous_criteria": ""
}